Funding
← Back to your selection

Bain Capital Life Sciences

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026
Rounds participated in
2
Confirmed lead rounds
1
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$376M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2

By primary sector

Biotech2

By country

United Kingdom1
United States1

Rounds

2 in this selection
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Lead
Abcuro

Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.

$66MSeries D
Role not disclosed